Translating imaging traits of mass-forming intrahepatic cholangiocarcinoma into the clinic: From prognostic to therapeutic insights
Gu-Wei Ji,
Qing Xu,
Chen-Yu Jiao,
Ming Lu,
Zheng-Gang Xu,
Biao Zhang,
Yue Yang,
Ke Wang,
Xiang-Cheng Li,
Xue-Hao Wang
Affiliations
Gu-Wei Ji
Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, PR China; Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, Nanjing, PR China; NHC Key Laboratory of Living Donor Liver Transplantation (Nanjing Medical University), Nanjing, PR China
Qing Xu
Department of Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, PR China; Corresponding authors. Address: Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, PR China. Tel: +86-13305178713; Fax: +86-68136450 (X.H. Wang); Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, PR China. Tel.: +86-18951999088; Fax: +86-68136450 (X.C. Li); Department of Radiology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, PR China. Tel.: +86-13776683209; Fax: +86-68136450 (Q. Xu).
Chen-Yu Jiao
Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, PR China; Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, Nanjing, PR China; NHC Key Laboratory of Living Donor Liver Transplantation (Nanjing Medical University), Nanjing, PR China
Ming Lu
Department of Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, PR China
Zheng-Gang Xu
Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, PR China; Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, Nanjing, PR China; NHC Key Laboratory of Living Donor Liver Transplantation (Nanjing Medical University), Nanjing, PR China
Biao Zhang
Department of General Surgery, Yancheng No.1 People’s Hospital, Yancheng, PR China
Yue Yang
Department of General Surgery, The First People’s Hospital of Changzhou, Changzhou, PR China
Ke Wang
Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, PR China; Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, Nanjing, PR China; NHC Key Laboratory of Living Donor Liver Transplantation (Nanjing Medical University), Nanjing, PR China
Xiang-Cheng Li
Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, PR China; Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, Nanjing, PR China; NHC Key Laboratory of Living Donor Liver Transplantation (Nanjing Medical University), Nanjing, PR China; Corresponding authors. Address: Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, PR China. Tel: +86-13305178713; Fax: +86-68136450 (X.H. Wang); Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, PR China. Tel.: +86-18951999088; Fax: +86-68136450 (X.C. Li); Department of Radiology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, PR China. Tel.: +86-13776683209; Fax: +86-68136450 (Q. Xu).
Xue-Hao Wang
Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, PR China; Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, Nanjing, PR China; NHC Key Laboratory of Living Donor Liver Transplantation (Nanjing Medical University), Nanjing, PR China; Corresponding authors. Address: Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, PR China. Tel: +86-13305178713; Fax: +86-68136450 (X.H. Wang); Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, PR China. Tel.: +86-18951999088; Fax: +86-68136450 (X.C. Li); Department of Radiology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, PR China. Tel.: +86-13776683209; Fax: +86-68136450 (Q. Xu).
Background & Aims: The progress toward clinical translation of imaging biomarkers for mass-forming intrahepatic cholangiocarcinoma (MICC) is slower than anticipated. Questions remain on the biologic behaviour underlying imaging traits. We developed and validated imaging-based prognostic systems for resected MICCs with an appraisal of the tumour immune microenvironment (TIME) underpinning patient-specific imaging traits. Methods: Between January 2009 and December 2019, a total of 322 patients who underwent dynamic computed tomography/magnetic resonance imaging and curative-intent resection for MICC at three hepatobiliary institutions were retrospectively recruited, divided into training (n = 193) and validation (n = 129) datasets. Two radiological and clinical scoring (RACS) systems, one integrating preoperative variables and one integrating preoperative and postoperative variables, were developed using Cox regression analysis. We then prospectively analysed the TIME of tissue samples from 20 patients who met study criteria from January 2021 to December 2021 using multiplexed immunofluorescence. Results: Preoperative and postoperative MICC-RACS systems built on carbohydrate antigen 19-9, albumin, tumour number, radiological/pathological nodal status, pathological necrosis, and three radiological traits (arterial enhancement pattern, tumour boundary, and capsular retraction) demonstrated good performance in predicting disease-specific (C-statistic >0.80) and disease-free (C-statistic >0.75) survival that outperformed rival models and staging systems across study cohorts (P <0.05 for all). Patients with MICC-RACS score of 0–2 (low risk), 3–5 (medium risk), and ≥6 (high risk) had incrementally worse prognosis after surgery. Significant differences in spatial distribution and infiltration level of immune cells were identified between arterial enhancement patterns. Enhanced infiltration of immunosuppressive regulatory T cells and M2-like macrophages at the invasive margin were noted in tumours with distinct boundary and capsular retraction, respectively. Conclusions: Our MICC-RACS systems are simple but powerful prognostic tools that may facilitate the understanding of spatially distinct TIMEs and patient-tailored immunotherapy approach. Impact and Implications: The progress toward clinical translation of imaging biomarkers for mass-forming intrahepatic cholangiocarcinoma (MICC) is slower than anticipated. Questions remain on the biologic behaviour of MICC underlying imaging traits. In this study, we proposed novel and easy-to-use tools, built on radiological and clinical features, that demonstrated good performance in predicting the prognosis either before or after surgery and outperformed rival models/systems across major imaging modalities. The characteristic radiological traits integrated into prognostic systems (arterial enhancement pattern, tumour boundary, and capsular retraction) were highly correlated with heterogeneous tumour-immune microenvironments, thereby renovating treatment paradigms for this difficult-to-treat disease.